[Previous][Table of Contents][Next]
Only confirmed cases of disease should be notified.
Routine case-by-case notification to the federal level
Enhanced case-by-case notification to International Circumpolar Surveillance in participating Northern regions
Enhanced active case-by-case notification by paediatric tertiary care hospitals involved in the Immunization Monitoring Program, Active (IMPACT)
Clinical evidence of invasive disease (see section 5.0) with laboratory confirmation of infection:
Clinical evidence of invasive disease with no other apparent cause and with nonconfirmatory laboratory evidence:
Sputum and bronchial lavages are not considered sterile specimens.
Demonstration of S. pneumoniae DNA or antigen does not permit determination of serotype. Serotyping is carried out in a reference laboratory and is important for monitoring changes in disease epidemiology, including the impact of vaccination programs and serotype replacement.
Clinical illness associated with invasive disease manifests itself mainly as pneumonia with bacteremia, bacteremia without a known site of infection, and meningitis. Pneumonia without bacteremia is not notifiable.
Probable case definitions are provided as guidelines to assist with case finding and public health management, and are not for national notification purposes.
Laboratory Centre for Disease Control. Preventing pneumococcal disease: a Canadian consensus conference. CCDR 1999;25:25-35.
Case definitions for diseases under national surveillance. CCDR 2000;26(S3).
May 2008
[Previous][Table of Contents][Next]
To share this page just click on the social network icon of your choice.